15mg Mounjaro Pens: Facts About the Maximum Dose

15mg is the maximum licensed dose of tirzepatide (Mounjaro) in the UK — each pen contains four once-weekly doses.
In the SURMOUNT-1 clinical trial, participants at 15mg achieved an average body-weight reduction of around 20–21% over 72 weeks.
Reaching 15mg requires completing the full titration schedule from 2.5mg; a prescriber decides whether each dose increase is appropriate.
The 15mg pen shares the same KwikPen format as all other Mounjaro strengths, same injection technique, same storage conditions.

The 15mg Mounjaro pen is the highest licensed dose of tirzepatide available in the UK, reached after a gradual titration that typically spans around six months. It is not a starting point — it is where treatment may arrive, once your body has adjusted through the lower doses. As a prescription-only medicine, whether 15mg is right for you is a clinical judgement, not a self-selection. The NHS medicines page for tirzepatide gives a clear patient-level overview of the full dose range and what to expect at each stage.

Starting from £29.99/mo

Free 2-minute consultation · Reviewed same day

Start journey
The nume Promise

Order by 12pm.

At your door the next working day.
Free, tracked, plain packaging.

Guaranteed on approved orders

Where are you starting from?

BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.

Check your BMI.

Ten seconds. Private — nothing is stored or shared.

80 kg
170 cm

Your result updates live in the card alongside.

Your result

Your BMI is

which is in the healthy weight range

Start journey

BMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.

Treatment options

Weight loss treatments

The problem

Most weight loss services treat you like a transaction, a checkout, a courier, and you're on your own.

Algorithm approvalsNo real clinicianGeneric dosingHidden feesSlow deliverySilence after checkout

The nume way

We built the opposite: one clinician who knows you, guaranteed care at every step.

24 hrs

clinician review. Free next working day delivery.

How it works

From consultation to your door, properly.

Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.

Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.

Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.

The full picture on 15mg Mounjaro: what the evidence says and what patients often get wrong

The biggest misconception: 15mg is not the target, it's the ceiling

A question our prescribers hear most weeks is some version of: 'When do I get onto the 15mg pen?' The assumption behind it is understandable, higher dose, more weight lost, get there fast. The reality is more nuanced. Tirzepatide's titration schedule exists specifically to reduce side effects, particularly the nausea and digestive discomfort that can follow a dose step-up. Starting at 2.5mg and moving upwards in roughly four-week steps isn't a formality. It's the reason most people tolerate the medicine well enough to stay on it.

Not everyone reaches 15mg, and that's not a failure. Some people respond well at 10mg or 12.5mg and their prescriber judges there's no clinical reason to push higher. Others need 15mg to maintain progress. The maintenance dose for Mounjaro is the highest dose you tolerate well and that continues to support your goals, for some people that is 15mg, for others it isn't. The decision sits with your prescriber, not the dose ladder itself.

The full titration schedule (and what happens at each step) is covered in detail on the Mounjaro dosage guide, which is worth reading before any consultation.

What the trial evidence actually shows at 15mg

SURMOUNT-1, published in the New England Journal of Medicine, is the landmark phase 3 trial for tirzepatide in adults with obesity. At 15mg over 72 weeks, participants achieved an average body-weight reduction of around 20–21%. Some analyses put it slightly higher (around 22.5%) among those who completed the full course. These are averages across thousands of adults; individual results vary, and no outcome is guaranteed.

What SURMOUNT-1 also showed is that the gap between 10mg and 15mg is real but not dramatic. The step from 10mg to 15mg added meaningful average weight loss in the trial data, but it came with a slightly higher rate of gastrointestinal side effects. That trade-off is part of what your prescriber weighs up before recommending a dose increase.

NICE's appraisal of tirzepatide, published as TA1026, draws on this evidence base. It notes that tirzepatide produced greater average weight reduction than semaglutide 2.4mg in direct head-to-head comparison, with the 15mg dose driving much of that advantage. The NICE appraisal is the formal basis on which tirzepatide is recommended within the NHS.

For a broader look at tirzepatide as a treatment (mechanism, eligibility and how it compares to other options) the Mounjaro overview covers the full picture.

The 15mg pen in practice: clicks, technique and storage

Each Mounjaro KwikPen, at every strength, contains four doses. The 15mg pen is no different in size or use from the 2.5mg pen, same pre-filled design, same subcutaneous injection technique, same rotation of sites (abdomen, thigh or upper arm). What does change is the number of clicks the dial advances through before an injection is complete. If you're curious about that specific mechanic, the 15mg pen clicks guide explains it precisely.

Storage follows the same principles as all Mounjaro strengths: refrigerated between 2°C and 8°C. There is a limited window during which an unrefrigerated pen remains usable, the exact duration is in the Patient Information Leaflet and on the eMC SmPC, and those are the authoritative sources. Don't rely on a remembered number from a forum. The leaflet that comes with your pen is the one to follow.

If you've seen the 15mg dose described elsewhere as tirzepatide 15mg, that's simply the INN (international non-proprietary name) for the same medicine, Mounjaro is the UK brand name.

Cost context and getting access

The 15mg pen sits at the higher end of the private market price range for Mounjaro. Eli Lilly raised UK list prices from September 2025, and private prices at the highest dose have typically ranged from roughly £300–£375 per four-week pen since then, depending on provider. Those figures are reported market context, not a price quote, actual treatment pricing varies and is confirmed at consultation.

Broadly, Mounjaro pricing reflects both the dose strength and what a given service includes. Some providers quote a per-pen price that excludes consultation fees, prescription charges and delivery. Others include everything in a single figure. Worth asking before you commit.

One practical note: reaching 15mg through a private route means each dose step is clinically reviewed before it's dispensed. At nume, no dose increase is processed automatically. A prescriber checks that the previous dose has been tolerated appropriately and that progressing makes clinical sense. That review happens before every repeat, not just at the start.

If you're weighing up your options, the free consultation is the natural starting point. A GPhC-registered prescriber reads your answers the same day and advises on what dose, if any, is appropriate for you. No obligation, no automated approval process.

Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.
Start free consultation

The people

Meet the team.

Mahommed Zunaid Ayub Patel

Superintendent Pharmacist (GPhC No. 2217101)

Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.

Mostafa Damghani

Clinical Lead (GPhC No. 2231744)

Sets our clinical standards and checks everything we publish against current MHRA guidance.

Shelan Salih

Independent Prescriber (GPhC No. 2084501)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Rehenaaz Uddin

Independent Prescriber (GPhC No. 2083426)

Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.

Frequently asked questions